Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM.
Dimethyl fumarate
Multiple sclerosis
Safety and effectiveness
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
02
04
2020
pubmed:
31
5
2020
medline:
31
5
2020
entrez:
31
5
2020
Statut:
ppublish
Résumé
Compared with the non-Hispanic/non-Latino population, Hispanic/Latino patients with multiple sclerosis (MS) are reported to exhibit greater disease severity. Geographical location and genetics play a role in differences observed across Hispanic/Latino subpopulations. We evaluated real-world safety and effectiveness of dimethyl fumarate (DMF) on MS disease activity in Hispanic/Latino patients. ESTEEM is an ongoing, 5-year, multinational, prospective study evaluating long-term safety and effectiveness of DMF in patients with MS. This interim analysis included patients newly prescribed DMF in routine practice at 394 sites globally. Overall, 4986 non-Hispanic/non-Latino and 98 Hispanic/Latino patients were analyzed; median (range) follow-up was 18 (2-37) months. Unadjusted annualized relapse rates (ARRs) for 12 months before DMF initiation versus 36 months post DMF initiation, respectively, were: non-Hispanic/non-Latino patients, 0.82 (95% CI 0.80-0.84) versus 0.10 (95% CI 0.09-0.10), 88% lower ARR (P < 0.0001); Hispanic/Latino patients, 0.80 (95% CI 0.65-1.00) versus 0.09 (95% CI 0.06-0.14), 89% lower ARR (P < 0.0001). In total, 28 (29%) Hispanic/Latino patients reported adverse events leading to treatment discontinuation; gastrointestinal (GI) disorders (n = 10, 10%) were the most common, consistent with the non-Hispanic/non-Latino population (8%). Median lymphocyte counts decreased by approximately 24% in the first year (vs 36% decrease in non-Hispanic/non-Latino patients) then remained stable and above the lower limit of normal in most patients. Relapse rates remained low in Hispanic/Latino patients, consistent with non-Hispanic/non-Latino patients. The safety profile of DMF in Hispanic/Latino patients was consistent with safety findings from the non-Hispanic/non-Latino ESTEEM population, demonstrating the real-world treatment benefit of DMF in the Hispanic/Latino patient cohort.
Identifiants
pubmed: 32472385
doi: 10.1007/s40120-020-00192-6
pii: 10.1007/s40120-020-00192-6
pmc: PMC7606387
doi:
Types de publication
Journal Article
Langues
eng
Pagination
495-504Références
Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132–42.
doi: 10.1212/CPJ.0000000000000112
pubmed: 26137421
pmcid: 26137421
TECFIDERA. TECFIDERA
US Food and Drug Administration. VUMERITY™ (diroximel fumarate) delayed-release capsules, for oral use. Highlights of prescribing information Cambridge, MA, USA: Biogen Inc.; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf . Accessed 10 Sept 2019.
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.
doi: 10.1056/NEJMoa1206328
Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253–65.
doi: 10.1177/1352458516649037
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.
doi: 10.1056/NEJMoa1114287
Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL. Efficacy and tolerability of delayed-release dimethyl fumarate in black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM. Neurol Ther. 2017;6(2):175–87.
doi: 10.1007/s40120-017-0077-5
pubmed: 28770420
pmcid: 5700899
Gadoth N. Multiple sclerosis in children. Brain Dev. 2003;25(4):229–32.
doi: 10.1016/S0387-7604(03)00035-4
pubmed: 12767451
pmcid: 12767451
Zhovtis Ryerson L, Green R, Confident G, et al. Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic-Americans with multiple sclerosis. Ther Adv Neurol Disord. 2016;9(6):454–61.
doi: 10.1177/1756285616661929
pubmed: 27800021
pmcid: 5066529
Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Adv Ther. 2014;31(10):1072–81.
doi: 10.1007/s12325-014-0154-4
pubmed: 25245812
Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL. Efficacy and tolerability of delayed-release dimethyl fumarate in Black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM. Neurol Ther. 2017;6(2):175–87.
doi: 10.1007/s40120-017-0077-5
pubmed: 28770420
pmcid: 5700899
Mao X, Bigham AW, Mei R, et al. A genomewide admixture mapping panel for Hispanic/Latino populations. Am J Hum Genet. 2007;80(6):1171–8.
doi: 10.1086/518564
pubmed: 17503334
pmcid: 1867104
Price AL, Patterson N, Yu F, et al. A genomewide admixture map for Latino populations. Am J Hum Genet. 2007;80(6):1024–36.
doi: 10.1086/518313
pubmed: 17503322
pmcid: 1867092
Hadjixenofontos A, Beecham AH, Manrique CP, et al. Clinical expression of multiple sclerosis in Hispanic Whites of primarily Caribbean ancestry. Neuroepidemiology. 2015;44(4):262–8.
doi: 10.1159/000431375
pubmed: 26184860
Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80(19):1734–9.
doi: 10.1212/WNL.0b013e3182918cc2
pubmed: 23650231
Williams M, Amezcua L, Okai A, Okuda DT, Cohan S, Su R, Parks B, Mendoza JP, Lewin JB, Jones CC. Real-world safety and effectiveness of dimethyl fumarate in Black or African American patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020 in press.